CEPI rewards Novavax $384 million for COVID-19 vaccine development

After receiving a $4 million award back in March for early vaccine work, Novavax has recently been rewarded the Coalition for Epidemic Preparedness Innovations’ (CEPI) largest investment of $384 million, aiding COVID-19 vaccine development. Also, the investment will fund Novavax’s COVID-19 vaccine testing through phase two, as well as ramp-up manufacturing to make 100 million doses by the end of 2020, and over 1 billion doses in 2021.

While rewarding funds to Novavax, CEPI has also distributed rewards to Inovio Pharmaceuticals, Moderna, Institut Pasteur’s group, the University of Hong Kong, the University of Queensland, the University of Oxford and Curevac.